DrugCite
Search

DIFFU K

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Diffu K Adverse Events Reported to the FDA Over Time

How are Diffu K adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Diffu K, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Diffu K is flagged as the suspect drug causing the adverse event.

Most Common Diffu K Adverse Events Reported to the FDA

What are the most common Diffu K adverse events reported to the FDA?

Renal Failure Acute
38 (3.37%)
Hyperkalaemia
35 (3.11%)
Dehydration
24 (2.13%)
Diarrhoea
22 (1.95%)
Dyspnoea
20 (1.78%)
Vomiting
20 (1.78%)
Pulmonary Arterial Hypertension
18 (1.6%)
Renal Failure
17 (1.51%)
Cholestasis
16 (1.42%)
Overdose
16 (1.42%)
Bradycardia
14 (1.24%)
Show More Show More
Hyponatraemia
14 (1.24%)
Drug Interaction
13 (1.15%)
Fall
13 (1.15%)
Confusional State
12 (1.07%)
Nausea
12 (1.07%)
Pruritus
12 (1.07%)
Atrioventricular Block Complete
11 (.98%)
Cardio-respiratory Arrest
11 (.98%)
General Physical Health Deteriorati...
11 (.98%)
Hypotension
11 (.98%)
Malaise
11 (.98%)
Metabolic Acidosis
11 (.98%)
Rash Erythematous
11 (.98%)
Hypercapnia
10 (.89%)
Cytolytic Hepatitis
9 (.8%)
Dyspnoea Exertional
9 (.8%)
Eosinophilia
9 (.8%)
Gastrointestinal Haemorrhage
9 (.8%)
Somnolence
9 (.8%)
Tachycardia
9 (.8%)
Thrombocytopenia
9 (.8%)
Blood Creatinine Increased
8 (.71%)
Cardiac Arrest
8 (.71%)
Cardiac Failure
8 (.71%)
Hypovolaemia
8 (.71%)
Jaundice
8 (.71%)
Mitral Valve Incompetence
8 (.71%)
Pelvic Pain
8 (.71%)
Rash Maculo-papular
8 (.71%)
Agitation
7 (.62%)
Asthenia
7 (.62%)
Myocardial Infarction
7 (.62%)
Toxic Skin Eruption
7 (.62%)
Arrhythmia
6 (.53%)
Blood Urea Increased
6 (.53%)
Coma
6 (.53%)
Faecal Vomiting
6 (.53%)
Food Intolerance
6 (.53%)
Haemodynamic Instability
6 (.53%)
Haemoglobin Decreased
6 (.53%)
Loss Of Consciousness
6 (.53%)
Rectal Haemorrhage
6 (.53%)
Acute Generalised Exanthematous Pus...
5 (.44%)
Aortic Valve Incompetence
5 (.44%)
Atrial Fibrillation
5 (.44%)
Death
5 (.44%)
Electrocardiogram Qrs Complex Prolo...
5 (.44%)
Encephalopathy
5 (.44%)
Haemodialysis
5 (.44%)
Haemorrhoids
5 (.44%)
Hyperlactacidaemia
5 (.44%)
Metabolic Alkalosis
5 (.44%)
Pyrexia
5 (.44%)
Rash Generalised
5 (.44%)
Rash Pustular
5 (.44%)
Wound
5 (.44%)
Anaemia
4 (.36%)
Arteriospasm Coronary
4 (.36%)
Asterixis
4 (.36%)
Blood Alkaline Phosphatase Increase...
4 (.36%)
Blood Bilirubin Increased
4 (.36%)
Depressed Level Of Consciousness
4 (.36%)
Disseminated Intravascular Coagulat...
4 (.36%)
Gamma-glutamyltransferase Increased
4 (.36%)
Infarction
4 (.36%)
Mental Disorder
4 (.36%)
Oxygen Saturation Decreased
4 (.36%)
Pancreatitis Acute
4 (.36%)
Peripheral Motor Neuropathy
4 (.36%)
Pulmonary Embolism
4 (.36%)
Rash Papular
4 (.36%)
Respiratory Arrest
4 (.36%)
Abdominal Pain
3 (.27%)
Anaphylactic Shock
3 (.27%)
Aortic Valve Disease
3 (.27%)
Blood Potassium Decreased
3 (.27%)
Blood Sodium Decreased
3 (.27%)
Candidiasis
3 (.27%)
Cholelithiasis
3 (.27%)
Cyanosis
3 (.27%)
Drug Eruption
3 (.27%)
Ejection Fraction Decreased
3 (.27%)
Endocarditis Candida
3 (.27%)
Generalised Erythema
3 (.27%)
Hepatic Encephalopathy
3 (.27%)
Hepatic Enzyme Increased
3 (.27%)
Hepatic Failure
3 (.27%)
Hepatic Steatosis
3 (.27%)
Hepatitis Fulminant
3 (.27%)
Hyperkeratosis
3 (.27%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Diffu K, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Diffu K is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Diffu K

What are the most common Diffu K adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Diffu K, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Diffu K is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Diffu K According to Those Reporting Adverse Events

Why are people taking Diffu K, according to those reporting adverse events to the FDA?

Drug Use For Unknown Indication
160
Hypokalaemia
82
Product Used For Unknown Indication
53
Prophylaxis
19
Ill-defined Disorder
12
Unevaluable Event
11
Show More Show More
Ventricular Extrasystoles
9
Hypertension
6
Mineral Supplementation
5
Blood Potassium Decreased
4
Cardiac Disorder
3
Rheumatoid Arthritis
2
Medical Diet
2
Constipation
1
Acute Coronary Syndrome
1
Electrolyte Substitution Therapy
1
Ischaemic Cardiomyopathy
1
Therapeutic Procedure
1
Cardiac Failure
1
Myocardial Infarction
1
Hiv Infection
1
Myocardial Ischaemia
1
Diuretic Therapy
1

Diffu K Case Reports

What Diffu K safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Diffu K. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Diffu K.